Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis

Bibliography

• Wilke H, Muro K, Van Cutsem EV, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-35
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):31-9
   PubMed Web of Science ®Google Scholar
• Mackey JR, Ramos-Vazquez M, Lipatov O, et al. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol 2015;33(2):141-8
   PubMed Web of Science ®Google Scholar
• Tabernero J, Cohn AL, Obermannova R, et al. RAISE: a randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol 2015;33(Suppl 3):Abstract 512
   Google Scholar
• Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2014;2(12):123
   PubMedGoogle Scholar
• Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit Rev Oncol Hematol 2015;93(1):18-27
   PubMed Web of Science ®Google Scholar
• Bozza C, Fontanella C, Buoro V, et al. Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue? Expert Rev Clin Pharmacol 2015;8(2):1-15
   PubMedGoogle Scholar
• Aprile G, Rijavec E, Fontanella C, et al. Ramucirumab: preclinical research and clinical development. OncoTargets Ther 2014;7:1997-2006
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62(10):1006-12
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta analyses. BMJ 2003;327(7414):557-60
   PubMed Web of Science ®Google Scholar
• Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. Tumor Biol 2014;35(11):10615-25
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis. Expert Rev Anticancer Ther 2015;15(4):465-75
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies. Expert Rev Anticancer Ther 2014;14(10):1229-42
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. Expert Rev Anticancer Ther 2015;15(7):1-12
   PubMed Web of Science ®Google Scholar
• Santoni M, Conti A, De Giorgi U, et al. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta analysis of clinical trials. Int J Cancer 2014;135(4):763-73
   PubMed Web of Science ®Google Scholar
• Gruenwald V, Weikert S, Pavel ME, et al. Practical management of everolimus-related toxicities in patients with advanced solid tumors. Onkologie 2013;36(5):295-302
   PubMed Web of Science ®Google Scholar
• Walraven M, Witteveen PO, Lolkema MP, et al. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 2011;14(2):135-41
   PubMed Web of Science ®Google Scholar
• Tol J, Cats A, Mol L, et al. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs 2008;26(4):393-39
   PubMed Web of Science ®Google Scholar
• Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: A meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol 2014;70(8):893-906
   PubMed Web of Science ®Google Scholar
• Qi WX, Sun YJ, Tang LN, et al. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2014;89(3):394-403
   PubMed Web of Science ®Google Scholar
• Qi WX, Shen F, Qing Z, Xiao-Mao G. Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis. Tumor Biol 2014;35(11):10715-22
   PubMed Web of Science ®Google Scholar
• Diaz JP, Tew WP, Zivanovic O, et al. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol 2010;116(3):335-9
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2014;32(12):1210-17
   PubMed Web of Science ®Google Scholar
• Tanyi JL, McCann G, Hagemann AR, et al. Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol 2011;120(3):464-9
   PubMed Web of Science ®Google Scholar
• Borofsky SE, Levine MS, Rubesin SE, et al. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients. Abdom Imaging 2013;38(2):265-72
   PubMed Web of Science ®Google Scholar
• Kube R, Meyer F, Bien N, et al. [Surgical management of bevacizumab-associated peritonitis due to perforation]. Zentralbl Chir 2009;134(5):462-7
   PubMed Web of Science ®Google Scholar
• Available from: http://ec.europa.eu/health/documents/community-register/2014/20141219130327/anx_130327_en.pdf [Last accessed 15 April 2015]
   Google Scholar
• Yardley DA, Richards PD, Reeves JA, et al. Final results of a phase 2 study of ramucirumab (RAM) plus erbulin (E) versus E in advanced metastatic breast cancer (MBC). J Clin Oncol 2014;32(Suppl 5):Abstract 1035
   Google Scholar
• Yoon HH, Bendell JC, Braiteh FS, et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. J Clin Oncol 2014;32(15 Suppl):Abstract 4004
   Google Scholar
• Doebele RC, Spigel D, Tehfe M, et al. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 2014
   PubMed Web of Science ®Google Scholar
• Available from: https://clinicaltrials.gov/ct2/show/results/NCT01160744?term=ramucirumab&rank=38&sect=X01256#all [Last accessed 31 March 2015]
   Google Scholar
• Zhu AX, Ryoo BY, Yen CJ, et al. Ramucirumab as second-linetreatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: results from the randomized phase III REACH trial. Ann Oncol 2014;25(Suppl 5):v1-41
   Google Scholar
• Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384(9944):665-73
   PubMed Web of Science ®Google Scholar
• Hussain M, Rathkopf DE, Liu G, et al. A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy. J Clin Oncol 2012;30(Suppl 5):Abstract 97
   Google Scholar